Literature DB >> 32815153

Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution.

Haruhiko Takeda1, Atsushi Takai1, Ken Kumagai1, Eriko Iguchi1, Soichi Arasawa1, Yuji Eso1, Takahiro Shimizu1, Yoshihide Ueda1, Kojiro Taura2, Shinji Uemoto2, Ryuichi Kita3, Hironori Haga4, Hiroyuki Marusawa1,3, Akihiro Fujimoto5, Hiroshi Seno1.   

Abstract

Recent genetic analyses revealed genetic heterogeneity in hepatocellular carcinoma (HCC), although it remains unclear how genetic alterations contribute to the multistage progression of HCC, especially the early step from hypovascular liver nodules to hypervascular HCC. We conducted multiregional whole-genome sequencing on HCCs with a nodule-in-nodule appearance, consisting of inner hypervascular HCC surrounded by hypovascular HCC arising from a common origin, and identified point mutations, structural variations, and copy-number variations in each specimen. According to the genetic landscape of the inner and outer regions, together with the pathological and radiological findings, we examined the stepwise evolution of cancer cells from slow-growing HCC to rapid-growing HCC. We first demonstrated that most tumor cells consisting of hypovascular well-differentiated HCCs already harbored thousands of point mutations and even several structural variations, including chromosomal translocations and chromothripsis, as the trunk events. Telomerase reverse transcriptase (TERT)-associated aberrations, including promoter mutations, chromosomal translocation, and hepatitis B virus DNA integration, as well as abnormal methylation status, were commonly detected as the trunk aberrations, while various liver cancer-related genes, which differed in each case, had additionally accumulated in the inner dedifferentiated nodules. Further, differences in the trunk and branch mutational signatures suggested a multistep contribution to the mutagenesis in each case. In conclusion, genomic alterations associated with the TERT gene could be the key driver events to form the hypovascular HCC, and additional case-specific driver mutations accumulate during the progression phase, forming intra- and inter-tumoral heterogeneity, confirming the importance of genetic testing before targeting therapy. These data shed light on the process of multistep hepatocarcinogenesis and will be helpful toward investigating new therapeutic strategies for HCC.
© 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  TERT; cancer evolution; early hepatocellular carcinoma; genetic landscape; hepatocarcinogenesis; heterogeneity; structural variation

Year:  2020        PMID: 32815153     DOI: 10.1002/path.5533

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  5 in total

Review 1.  Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics.

Authors:  Taiji Yamazoe; Taizo Mori; Sachiyo Yoshio; Tatsuya Kanto
Journal:  Glob Health Med       Date:  2020-10-31

2.  Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence.

Authors:  Shao-Lai Zhou; Zheng-Jun Zhou; Cheng-Li Song; Hao-Yang Xin; Zhi-Qiang Hu; Chu-Bin Luo; Yi-Jie Luo; Jia Li; Zhi Dai; Xin-Rong Yang; Ying-Hong Shi; Zheng Wang; Xiao-Wu Huang; Jia Fan; Jian Zhou
Journal:  Signal Transduct Target Ther       Date:  2022-01-26

Review 3.  Genetic Landscape of Multistep Hepatocarcinogenesis.

Authors:  Haruhiko Takeda; Atsushi Takai; Yuji Eso; Ken Takahashi; Hiroyuki Marusawa; Hiroshi Seno
Journal:  Cancers (Basel)       Date:  2022-01-23       Impact factor: 6.639

Review 4.  Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication.

Authors:  Natsumi Oe; Haruhiko Takeda; Yuji Eso; Atsushi Takai; Hiroyuki Marusawa
Journal:  Pathogens       Date:  2022-04-01

Review 5.  Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.

Authors:  Masayuki Ueno; Haruhiko Takeda; Atsushi Takai; Hiroshi Seno
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.